NCT02299648

The Screening Protocol for The VIKTORY Trial

Completed NA Last updated 15 June 2022

What this trial tests

NA trial testing Molecular profiling in Stomach Neoplasms in 651 participants. Completed in 17 May 2022.

Timeline

25 July 2014

Primary endpoint
30 December 2021

17 May 2022

Quick facts

Lead sponsor	Samsung Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	651
Start date	25 July 2014
Primary completion	30 December 2021
Estimated completion	17 May 2022
Sites	2 locations across South Korea

Drugs / interventions tested

• Molecular profiling

Conditions studied

• Stomach Neoplasms — all drugs for Stomach Neoplasms →

Sponsor

Samsung Medical Center

Who can join

18 and older, any sex, with Stomach Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This protocol is a screening protocol only. No drug intervention study will be included in this protocol. However, based on the molecular profiling, patients may be eligible for targeted agents. However, the molecular profiling doesn't guarantee the enrollment onto the clinical trial. Currently, the available drugs are AKT inhibitor, MEK inhibitor, Wee1 inhibitor, MET inhibitor. ATR inhibitor and other agents may be available in the context of clinical trials depending on the availability.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Signaling pathways and therapeutic interventions in gastric cancer.
   Lei ZN, Teng QX, Tian Q, Chen W, et al · · 2022 · cited 220× · PMID 36209270 · DOI 10.1038/s41392-022-01190-w
2. Targeting Akt in cancer for precision therapy.
   Hua H, Zhang H, Chen J, Wang J, et al · · 2021 · cited 182× · PMID 34419139 · DOI 10.1186/s13045-021-01137-8
3. MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.
   Dong Y, Xu J, Sun B, Wang J, et al · · 2022 · cited 50× · PMID 35266116 · DOI 10.1007/s40291-021-00568-w
4. Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma.
   Nagaraja AK, Kikuchi O, Bass AJ. · · 2019 · cited 42× · PMID 31727671 · DOI 10.1158/2159-8290.cd-19-0487
5. A Canadian guideline on the use of next-generation sequencing in oncology.
   Yip S, Christofides A, Banerji S, Downes MR, et al · · 2019 · cited 39× · PMID 31043833 · DOI 10.3747/co.26.4731
6. Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in <i>MET</i>-Amplified Gastric Cancer.
   Frigault MM, Markovets A, Nuttall B, Kim KM, et al · · 2020 · cited 16× · PMID 32923890 · DOI 10.1200/po.19.00386
7. Novel clinical trial designs emerging from the molecular reclassification of cancer.
   Nikanjam M, Kato S, Allen T, Sicklick JK, et al · · 2025 · cited 15× · PMID 39841128 · DOI 10.3322/caac.21880
8. Emerging Therapeutic Targets and Future Directions in Advanced Gastric Cancer: A Comprehensive Review.
   Ratti M, Orlandi E, Toscani I, Vecchia S, et al · · 2024 · cited 10× · PMID 39123420 · DOI 10.3390/cancers16152692